Construction And Clinical Application Of The Immune Map Of Pancreatic Cancer Evolution

Study Overview

Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution

The intricate interplay between systemic immunity and tumors profoundly influences not only the onset and progression of tumors but also serves as a crucial window into understanding tumor evolution and treatment status. This project aims to establish a large, multi-center pancreatic cancer cohort and a standardized clinical sample repository, capturing multimodal immunity big data on pancreatic cancer occurrence, progression, and treatment response across the spatial dimension of "peripheral versus local" and the temporal dimension of "tumor evolution/pre- and post-treatment." By integrating patient imaging and clinical information, we will develop a technical platform for intelligent extraction and fusion analysis of cross-scale, multimodal data, thereby mapping the immunity landscape of pancreatic cancer evolution, identifying characteristic changes in immunity parameters, and devising an AI model for early pancreatic cancer diagnosis with high accuracy and robust generalization capabilities, while also exploring the model's interpretability. Additionally, we will focus on specific immune cell subsets associated with pancreatic cancer evolution and treatment response, elucidating their roles and mechanisms in the occurrence, development, and drug resistance of pancreatic cancer. This project will establish a high-quality, standardized, and shareable pancreatic cancer immunity sample and data repository, refine the framework for multi-dimensional immunity data fusion and analysis, and create a time-space atlas of local and systemic immunity in pancreatic cancer. This will facilitate a deeper understanding of the dynamics of systemic and local immunity in early-stage pancreatic cancer and at various stages of its evolution, offering novel insights and approaches for the diagnosis and treatment of pancreatic cancer.

N/A

Immune Evasion, Tumor
Pancreas Cancer

IDPEPDAC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2025-06-15	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-06-15
First Submitted that Met QC Criteria 2025-06-15	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2025-06-24
First Posted (ACTUAL) 2025-06-24	Results First Posted N/A	Last Verified 2025-06

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
: Conventional treatment queue
: Dynamic follow-up queue
: Neoadjuvant therapy queue

Primary Outcome Measures	Measure Description	Time Frame
Pancreatic tumor resection		From diagnosis to surgery

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Yangyang Wang

Phone Number: 13957830918

Email: 12418635@zju.edu.cn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:
1

Healthy individuals without benign or malignant liver, gallbladder, and pancreas diseases
Primary PDAC
Patients with benign pancreatic tumors
IPMN patients diagnosed by pathology/imaging

Having autoimmune diseases
Accompanied by other malignant tumors
History of tumor treatment (except thyroid cancer and breast cancer, cured for more than 5 years)
Acute infection
History of blood transfusion within the past 6 months, or use of drugs that affect peripheral blood components such as recombinant human erythropoietin and interleukin within 2 weeks
Organ decompensation dysfunction
Immunodeficiency syndrome
Hematological precancerous lesions
Accept immunosuppressive therapy
Diagnosed coagulation disease

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record